Centre National De La Recherche Scientifique

Elro Pharma Sarl

Immupharma Sa

Elro Pharma

Jean Paul Briand

Gilles Guichard

Ara G Hovanessian

Jose P Courty

Yamina Hamma

Robert H Zimmer

José Courty

Robert Zimmer

Chantal Devin

Annie Lang

Haixang Zhang

Haixing Zhang

Ara Hovanessian

Haixiang Zhang

A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).

Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation

The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing.

Optically pure compounds for improved therapeutic efficiency

Growing community of inventors

Strasbourg, France

Jean Paul Briand